SCHEMBL1078973

SCHEMBL1078973

CC(C)NC(C)C.OP(O)O

nearest known ligand 0.67

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28394174 1.00 TDP1 (0.67) TDP1
Ethylene SCHEMBL8575909 0.93 TDP1 (0.57) TDP1
SCHEMBL16910012 0.85 TDP1 (0.57) TDP1
Methyl Alcohol SCHEMBL2170375 0.82
Hydrogen Peroxide SCHEMBL135017 0.82 TDP1 (0.80) TDP1
Hydrogen Peroxide SCHEMBL135019 0.82
SCHEMBL1332279 0.82
SCHEMBL2020 0.82
Methyl Alcohol SCHEMBL21933067 0.78 TDP1 (0.73) TDP1
Isopropyl Alcohol SCHEMBL11224772 0.78 TDP1 (0.73) TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117651707-A Novel synthetic TLR4 receptor agonists 米兰-比可卡大学 2024-03-05 CN claimed
US-20240238325-A1 Artificial Nucleic Acid and Method for Delivery of Nucleic Acid Using the Same JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2024-07-18 US disclosed
EP-4331617-A1 ARTIFICIAL NUCLEIC ACID AND NUCLEIC ACID DELIVERING METHOD USING SAME Japan Science and Technology Agency (JP) 2024-03-06 EP disclosed
CN-117651707-A Novel synthetic TLR4 receptor agonists 米兰-比可卡大学 2024-03-05 CN disclosed
CN-115485384-A Modified short interfering nucleic acid (siNA) molecules and uses thereof 阿利戈斯治疗公司 2022-12-16 CN disclosed
EP-2260936-B1 Method for specifically located synthesis of nucleic acids on solid carriers CLONDIAG GMBH (DE) 2017-12-27 EP disclosed
US-20110160082-A1 Mobility-Modified Nucleobase Polymers and Methods of Using Same Life Technologies Corporation (US) 2011-06-30 US disclosed
US-7897338-B2 Mobility-modified nucleobase polymers and methods of using same APPLIED BIOSYSTEMS, LLC (US) 2011-03-01 US disclosed
EP-1814656-B1 METHOD FOR SPECIFICALLY LOCATED SYNTHESIS OF BIOPOLYMERS ON SOLID CARRIERS CLONDIAG GMBH (DE) 2011-01-05 EP disclosed
EP-2260936-A2 Method for specifically located synthesis of biopolymers on solid carriers CLONDIAG GmbH (DE) 2010-12-15 EP disclosed
EP-1084134-A4 ACTIVATORS FOR OLIGONUCLEOTIDE SYNTHESIS ISIS PHARMACEUTICALS INC (US) 2004-05-26 EP disclosed
EP-1379698-A1 MOBILITY-MODIFIED NUCLEOBASE POLYMERS AND METHODS OF USING SAME Applera Corporation (US) 2004-01-14 EP disclosed
US-20030153743-A1 Processes for the synthesis of oligomeric compounds MANOHARAN MUTHIAH (US) 2003-08-14 US disclosed
US-6531590-B1 Having bioreversible phosphate blocking groups, using a phosphoramite reactant carrying the phosphate blocking group; designed for cleavage by carboxyesterases to yield unprotected oligonucleotides ISIS PHARMACEUTICALS, INC. 2003-03-11 US disclosed
US-20020182602-A1 Mobility-modified nucleobase polymers and methods of using same APPLIED BIOSYSTEMS, INC. 2002-12-05 US disclosed
WO-2002083954-A1 MOBILITY-MODIFIED NUCLEOBASE POLYMERS AND METHODS OF USING SAME APPLERA CORPORATION (US) 2002-10-24 WO disclosed
EP-1084134-A1 ACTIVATORS FOR OLIGONUCLEOTIDE SYNTHESIS ISIS PHARMACEUTICALS, INC. (US) 2001-03-21 EP disclosed
WO-1999064434-A1 SYNTHETIC METHODS AND INTERMEDIATES FOR TRIESTER OLIGONUCLEOTIDES ISIS PHARMACEUTICALS, INC. (US) 1999-12-16 WO disclosed
WO-1999062922-A1 ACTIVATORS FOR OLIGONUCLEOTIDE SYNTHESIS ISIS PHARMACEUTICALS, INC. (US) 1999-12-09 WO disclosed
WO-1999055717-A1 PROCESSES FOR THE SYNTHESIS OF OLIGOMERIC COMPOUNDS ISIS PHARMACEUTICALS, INC. (US) 1999-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020182602-A1 Mobility-modified nucleobase polymers and methods of using same PCNA, PNKP, SAMHD1 TDP1 147/4885
US-20030153743-A1 Processes for the synthesis of oligomeric compounds PPIP5K2, NUDT21, NUDT1 TDP1 282/4885
US-20240238325-A1 Artificial Nucleic Acid and Method for Delivery of Nucleic Acid Using the Same HNRNPH3, RNASEH1, HNRNPA1 TDP1 520/4885
US-20110160082-A1 Mobility-Modified Nucleobase Polymers and Methods of Using Same PCNA, PNKP, SAMHD1 TDP1 147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.